26^th Global Nephrology, Urology and Kidney Failure Congress

Emerging Biomarkers in Nephrology

Emerging biomarkers in nephrology hold great promise for enhancing the diagnosis, monitoring, and treatment of kidney diseases. Traditional markers like serum creatinine have limitations in early detection and do not fully reflect kidney function or injury. Recent advancements in biomarker research have identified new molecules, such as neutrophil gelatinase-associated (NGAL), interleukin-18 (IL-18), and kidney injury molecule-1 (KIM-1), which offer insights into renal function and damage at earlier stages. These biomarkers can aid in diagnosing acute kidney injury (AKI), chronic kidney disease (CKD), and glomerular diseases more accurately and quickly. Furthermore, research into urinary biomarkers allows for non-invasive assessments, improving patient comfort and compliance. The integration of biomarkers into clinical practice can facilitate personalized treatment approaches, enabling tailored interventions based on individual patient profiles. However, challenges remain in standardizing biomarker tests and ensuring their availability in routine clinical settings. Continued research and collaboration among nephrologists, laboratory scientists, and pharmaceutical companies are essential to fully realize the potential of emerging biomarkers in transforming kidney care